About Calithera Biosciences (NASDAQ:CALA)
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839 in cell renal cell carcinoma. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CALA
CUSIPN/A
Phone650-870-1000
Debt
Debt-to-Equity RatioN/A
Current Ratio4.30%
Quick Ratio4.30%
Price-To-Earnings
Trailing P/E Ratio-7.06
Forward P/E Ratio-4.90
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.95 million
Price / Sales8.19
Cash FlowN/A
Price / CashN/A
Book Value$4.24 per share
Price / Book1.40
Profitability
EPS (Most Recent Fiscal Year)($0.84)
Net Income$-27,820,000.00
Net Margins-107.21%
Return on Equity-17.49%
Return on Assets-13.31%
Miscellaneous
Employees73
Outstanding Shares35,850,000
Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions
What is Calithera Biosciences' stock symbol?
Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."
How were Calithera Biosciences' earnings last quarter?
Calithera Biosciences (NASDAQ:CALA) announced its quarterly earnings data on Thursday, March, 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.09. The biotechnology company had revenue of $7.24 million for the quarter, compared to the consensus estimate of $7.28 million. Calithera Biosciences had a negative return on equity of 17.49% and a negative net margin of 107.21%. During the same quarter in the prior year, the company earned ($0.45) EPS. View Calithera Biosciences' Earnings History.
What price target have analysts set for CALA?
5 equities research analysts have issued 1-year price objectives for Calithera Biosciences' stock. Their predictions range from $14.00 to $20.00. On average, they anticipate Calithera Biosciences' share price to reach $17.6667 in the next year. View Analyst Ratings for Calithera Biosciences.
Who are some of Calithera Biosciences' key competitors?
Some companies that are related to Calithera Biosciences include Amarin (AMRN), ARMO BioSciences (ARMO), Mirati Therapeutics (MRTX), Eagle Pharmaceuticals (EGRX), Collegium Pharmaceutical (COLL), Deciphera Pharmaceuticals (DCPH), CymaBay Therapeutics (CBAY), Urogen Pharma (URGN), Vectura Group (VEGPF), OptiNose (OPTN), Adamas Pharmaceuticals (ADMS), NuCana (NCNA), GlycoMimetics (GLYC), Vanda Pharmaceuticals (VNDA) and Homology Medicines (FIXX).
Who are Calithera Biosciences' key executives?
Calithera Biosciences' management team includes the folowing people:
- Dr. Susan M. Molineaux, Co-Founder, CEO, Pres, Principal Financial Officer & Director (Age 64)
- Dr. Keith Orford M.D., Ph.D., Sr. VP of Clinical Devel. (Age 46)
- Ms. Stephanie Wong, Sr. VP of Fin., Sec. & Principal Accounting Officer (Age 44)
- Ms. Jennifer McNealey, VP of Investor Relations & Strategy
- Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer
Has Calithera Biosciences been receiving favorable news coverage?
News articles about CALA stock have trended somewhat positive on Tuesday, according to Accern Sentiment. The research group scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Calithera Biosciences earned a daily sentiment score of 0.13 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 49.30 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Calithera Biosciences?
Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Calithera Biosciences' stock price today?
One share of CALA stock can currently be purchased for approximately $5.93.
How big of a company is Calithera Biosciences?
Calithera Biosciences has a market capitalization of $218.65 million and generates $25.95 million in revenue each year. The biotechnology company earns $-27,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Calithera Biosciences employs 73 workers across the globe.
How can I contact Calithera Biosciences?
Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]
MarketBeat Community Rating for Calithera Biosciences (CALA)
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Calithera Biosciences (NASDAQ:CALA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Calithera Biosciences in the last 12 months. Their average twelve-month price target is $17.6667, suggesting that the stock has a possible upside of 197.92%. The high price target for CALA is $20.00 and the low price target for CALA is $14.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.83 | 2.83 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $17.6667 | $16.20 | $14.40 | $14.40 |
| Price Target Upside: | 197.92% upside | 133.09% upside | 9.15% downside | 9.15% downside |
Calithera Biosciences (NASDAQ:CALA) Consensus Price Target History
Calithera Biosciences (NASDAQ:CALA) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Calithera Biosciences (NASDAQ:CALA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Calithera Biosciences (NASDAQ CALA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 17.30%
Institutional Ownership Percentage: 68.52%
Calithera Biosciences (NASDAQ CALA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/28/2017 | Adage Capital Partners Gp, L.L | Major Shareholder | Sell | 576,000 | $15.64 | $9,008,640.00 | |  |
| 7/17/2017 | Keith Orford | VP | Sell | 2,120 | $18.31 | $38,817.20 | | |
| 7/6/2017 | Curtis Hecht | SVP | Sell | 700 | $18.00 | $12,600.00 | | |
| 5/19/2017 | Curtis Hecht | SVP | Sell | 650 | $16.00 | $10,400.00 | 14,910 | |
| 3/22/2017 | Adage Capital Partners Gp, L.L | Major Shareholder | Buy | 487,804 | $10.25 | $4,999,991.00 | | |
| 3/13/2017 | Curtis Hecht | SVP | Sell | 600 | $14.00 | $8,400.00 | 15,560 | |
| 11/16/2016 | Adage Capital Partners Gp, L.L | Major Shareholder | Buy | 500,000 | $3.15 | $1,575,000.00 | | |
| 11/16/2015 | Curtis Hecht | VP | Sell | 970 | $6.58 | $6,382.60 | 8,625 | |
| 9/23/2015 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 106,968 | $6.03 | $645,017.04 | | |
| 9/4/2015 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 90,300 | $5.93 | $535,479.00 | | |
| 8/28/2015 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 172,126 | $5.27 | $907,104.02 | | |
| 10/15/2014 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 181,700 | $6.96 | $1,264,632.00 | | |
| 10/7/2014 | Jean George | Director | Buy | 300,000 | $10.00 | $3,000,000.00 | | |
| 10/7/2014 | Morgenthaler Venture Partners | Major Shareholder | Buy | 350,000 | $10.00 | $3,500,000.00 | | |
| 10/1/2014 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 800,000 | $10.00 | $8,000,000.00 | | |
(Data available from 1/1/2013 forward)
Calithera Biosciences (NASDAQ CALA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Blog Exposure - FDA Granted Fast Track Designation to Calithera Biosciences’ CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma Treatment
finance.yahoo.com - April 20 at 8:46 AM |
 | US STOCKS ON THE MOVE-Morgan Stanley, Textron, CSX, Juniper, IBM, Dynagas, eBay, Tesla
www.nasdaq.com - April 18 at 5:28 PM |
 | Calithera's CB-839 Fast Track'd for advanced kidney cancer
seekingalpha.com - April 18 at 8:38 AM |
 | Randomized CANTATA trial open for enrollment
globenewswire.com - April 18 at 8:38 AM |
| Calithera Biosciences stock surges on news of FDA fast track designation for kidney cancer treatment
finance.yahoo.com - April 18 at 8:38 AM |
 | Calithera Biosciences (CALA) Cut to Hold at BidaskClub
www.americanbankingnews.com - April 17 at 4:17 PM |
| Calithera Biosciences to Present New Preclinical Data for CB-839 at AACR Annual Meeting 2018
finance.yahoo.com - April 13 at 8:49 AM |
| Calithera Biosciences (CALA) Expected to Post Quarterly Sales of $7.28 Million
www.americanbankingnews.com - April 13 at 5:01 AM |
| Brokerages Anticipate Calithera Biosciences (CALA) Will Announce Earnings of -$0.29 Per Share
www.americanbankingnews.com - April 11 at 1:06 AM |
 | Calithera Biosciences (CALA) PT Lowered to $12 at JMP Securities
www.streetinsider.com - April 9 at 8:47 AM |
| Calithera Biosciences' (CALA) Outperform Rating Reiterated at Leerink Swann
www.americanbankingnews.com - April 7 at 10:38 AM |
| Calithera Biosciences Inc (CALA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 4 at 7:29 PM |
| Calithera to Present at Needham & Company 17th Annual Healthcare Conference
finance.yahoo.com - March 31 at 8:36 AM |
| [$$] Dracen Pharma Grabs $36 Million Commitment from Deerfield
finance.yahoo.com - March 31 at 8:36 AM |
| BidaskClub Downgrades Calithera Biosciences (CALA) to Strong Sell
www.americanbankingnews.com - March 27 at 4:00 PM |
| Calithera Biosciences Inc (CALA) Expected to Announce Quarterly Sales of $7.28 Million
www.americanbankingnews.com - March 27 at 8:25 AM |
| Analysts Anticipate Calithera Biosciences Inc (CALA) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - March 25 at 3:10 AM |
| Calithera to Present at Needham & Company 17th Annual ... - GlobeNewswire (press release)
globenewswire.com - March 23 at 5:21 PM |
| Edited Transcript of CALA earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 8:36 AM |
| Calithera Biosciences (CALA) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 13 at 6:55 PM |
| Calithera Biosciences Inc to Post Q1 2019 Earnings of ($0.49) Per Share, William Blair Forecasts (CALA)
www.americanbankingnews.com - March 12 at 7:12 AM |
| Calithera Biosciences Inc (CALA) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 10 at 7:30 PM |
| Does Calithera Biosciences Inc’s (NASDAQ:CALA) Latest Financial Perfomance Look Strong?
finance.yahoo.com - March 9 at 8:49 AM |
| $7.28 Million in Sales Expected for Calithera Biosciences Inc (CALA) This Quarter
www.americanbankingnews.com - March 9 at 2:56 AM |
| Calithera Biosciences (CALA) Posts Quarterly Earnings Results, Misses Expectations By $0.09 EPS
www.americanbankingnews.com - March 8 at 9:13 PM |
| Calithera Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - March 8 at 6:15 PM |
| Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - March 8 at 6:15 PM |
| Calithera Biosciences Inc (CALA) Expected to Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - March 7 at 9:14 PM |
 | Why Calithera Biosciences (CALA) Might Surprise This Earnings Season
www.zacks.com - March 7 at 8:44 AM |
| Calithera to Present at Cowen & Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 8:36 AM |
| Calithera Biosciences to Report Fourth Quarter 2017 Financial Results on Thursday, March 8, 2018
finance.yahoo.com - March 2 at 8:37 AM |
| Ascend Capital LLC Has $5.79 Million Holdings in Calithera Biosciences Inc (CALA)
www.americanbankingnews.com - March 1 at 4:41 AM |
| William Blair Weighs in on Calithera Biosciences Inc's FY2022 Earnings (CALA)
www.americanbankingnews.com - February 26 at 10:08 AM |
| Calithera Biosciences Inc (CALA) Expected to Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - February 19 at 3:18 AM |
| Citigroup Upgrades Calithera Biosciences (CALA) to Buy
www.americanbankingnews.com - February 17 at 12:10 AM |
| Here's Why Calithera Biosciences, Inc. Rose as Much as 25.2% Today
finance.yahoo.com - February 16 at 5:06 PM |
| Calithera Biosciences Inc (CALA) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 13 at 7:30 PM |
| FY2021 EPS Estimates for Calithera Biosciences Inc (CALA) Reduced by Analyst
www.americanbankingnews.com - February 8 at 5:52 PM |
| Analysts Issue Forecasts for Calithera Biosciences Inc's FY2022 Earnings (CALA)
www.americanbankingnews.com - February 7 at 11:30 PM |
| Results from Phase I Study of CB-839 in Combination with Everolimus or Cabozantinib in Patients with Renal Cell Carcinoma to be Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancer Symposium
finance.yahoo.com - February 6 at 9:38 AM |
| Calithera Biosciences (CALA) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - February 3 at 1:34 PM |
| Calithera Biosciences Inc (CALA) Expected to Post Quarterly Sales of $7.28 Million
www.americanbankingnews.com - January 18 at 10:40 AM |
| Edited Transcript of CALA earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - January 3 at 5:11 PM |
| Calithera Biosciences (CALA) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - January 2 at 10:34 PM |
| Calithera Biosciences Inc (CALA) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 25 at 7:55 PM |
| BidaskClub Upgrades Calithera Biosciences (CALA) to Sell
www.americanbankingnews.com - December 22 at 10:01 PM |
| Zacks: Analysts Anticipate Calithera Biosciences Inc (CALA) Will Post Quarterly Sales of $7.28 Million
www.americanbankingnews.com - December 15 at 2:56 PM |
| Zacks: Analysts Anticipate Calithera Biosciences Inc (CALA) to Post -$0.24 EPS
www.americanbankingnews.com - December 13 at 8:32 AM |
| Calithera Biosciences (CALA) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - December 9 at 10:36 AM |
| Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium
finance.yahoo.com - December 5 at 10:25 AM |
Calithera Biosciences (NASDAQ:CALA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Calithera Biosciences (NASDAQ:CALA) Income Statement, Balance Sheet and Cash Flow Statement
Calithera Biosciences (NASDAQ CALA) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
